Dr. McMahon’s research focus has been on mechanisms of abnormal bleeding and clotting in specific disease states, particularly cancers/myeloproliferative neoplasms. This includes evaluating clinical risk factors for developing thrombotic or bleeding complications in specific disease states. He is also interested in clinical trials investigating novel therapeutic options in MPN.
Dr. McMahon’s past work has also evaluated use of diagnostic testing or therapeutic interventions in hematology that lack clinical validation, yet are commonly used in everyday practice.
Gerds AT, Gotlib J, Ali H, Bose P, Dunbar A, Elshoury A, George T, Gundabolu K, Hexner E, Hobbs GS, Jain T, Jamieson C, Kaesberg PR, Kuykendall AT, Madanat Y, McMahon B, Mohan SR, Nadiminti KV, Oh S, Pardanani A, Podoltsev N, Rein L, Salit R, Stein BL, Talpaz M, Vachhani P, Wadleigh M, Wall S, Ward DC, Bergman MA, Hochstetler C. Myeloproliferative Neoplasms version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw
. 2022 Sep;20(9):1033-1062. doi: 10.6004/jnccn.2022.004
Esparza O, McMahon B, Hernandez G, Le D, Kelher M, Nemkov T, D'Alessandro A, Lopez J, Davizon-Castillo P. Mitochondrial dysfunction in platelets from patients with JAK2 V617F essential thrombocythemia and polycythemia vera underlie thrombo-hemorrhagic complications [abstract]. ISTH Congress 2022.
Guadalupe Rojas Sanchez, Ph D1*, Orlando Esparza, MD2, Brandon McMahon, MD3, Giovanny Hernandez, BS4*, Dennis Le, BS1*, Travis Nemkov, PhD5*, Angelo D'Alessandro, PhD6, Andrew Thorburn, Ph D7*, José A. López, Pavel Davizon Castillo. Dysregulated Autophagy in Platelets from JAK2V617F-Positive Polycythemia Vera and Essential Thrombocythemia Underlies Bioenergetic Failure As a Possible Mechanism for Thrombohemorrhagic Complications. Abstract 4315, ASH 64th Annual Meeting and Exposition.
Shaikh SS, Kamath SD, Ghosh D, Lewandowski RJ, McMahon BJ. Safety and Outcomes of Permanent and Retrievable Inferior Vena Cava Filters in the Oncology Population. Int J Vasc Med. 2020;2020:6582742. PubMed PMID: 32089887
Kolb JM, Conzen K, Wachs M, Crossno J Jr, McMahon B, Abidi MZ, Pomfret EA, Kriss M. Liver Transplantation for Decompensated Cirrhosis Secondary to Telomerase Reverse Transcriptase Mutation. Hepatology. 2020 Jul;72(1):356-358. PubMed PMID: 31943309
Davizon-Castillo P, McMahon B, Aguila S, Bark D, Ashworth K, Allawzi A, Campbell RA, Montenont E, Nemkov T, D'Alessandro A, Clendenen N, Shih L, Sanders NA, Higa K, Cox A, Padilla-Romo Z, Hernandez G, Wartchow E, Trahan GD, Nozik-Grayck E, Jones K, Pietras EM, DeGregori J, Rondina MT, Di Paola J. TNF-a-driven inflammation and mitochondrial dysfunction define the platelet hyperreactivity of aging. Blood. 2019 Aug 29;134(9):727-740. PubMed PMID: 31311815
Wilberger AC, McMahon B, Ewalt MD. The power of the partner: defying expectations in a case of a myeloproliferative neoplasm with FGFR1 rearrangement. Leuk Lymphoma. 2019 Apr;60(4):1095-1097. PubMed PMID: 30277124
Dr. McMahon completed his undergraduate training at Boston College, where he received a Bachelor’s degree in Chemistry with honors. He graduated AOA with his M.D. from SUNY-Upstate Medical University at Syracuse, and then moved to the University of Rochester where he completed his internal medicine residency, followed by a chief residency. He remained that the University of Rochester for his hematology fellowship, which was completed in 2007, and during which he completed the American Society of Hematology Clinical Research Training Institute.
He joined the faculty at Northwestern University in Chicago as an Assistant Professor and later Associate Professor of Medicine, where he was heavily involved in clinical operations in hematology, clinical research in thrombotic disorders and MPN, and education, receiving multiple teaching awards and serving as the associate and later director of the Hematology/Oncology fellowship program. He joined the faculty at the University of Colorado in 2016, and will be focusing on thrombosis & MPN in the clinical arena, while remaining active in fellow & resident education.
Dr. McMahon’s research involves evaluating mechanisms of thrombotic and bleeding complications in various cancers (particularly MPN), critical evaluation of common medical practices in hematology that lack significant evidence basis, and clinical trials evaluating new therapeutic developments in MPN. He has written many peer-reviewed papers on these topics, several book chapters, and edited a recently published textbook on myeloproliferative neoplasms.
MD, State University of New York Upstate Medical University
BA/BS, Boston College (MA)
University of Rochester Program
University of Rochester Program, Chief Resident, Internal Medicine (2005)
University of Rochester Program, Hematology